LimmaTech Biologics Reports Positive Interim Phase I/II Clinical Data on Tetravalent Shigella Bioconjugate Vaccine S4V : vimarsana.com

SCHLIEREN, Switzerland, February 22, 2024--LimmaTech Biologics AG announced positive interim data from its Phase I/II clinical trial evaluating Shigella4V (S4V), a tetravalent bioconjugate vaccine candidate against shigellosis, an infectious disease caused by Shigella bacteria. Shigellosis is a serious infection and remains the second leading cause of fatal diarrheal disease, particularly in infants in low- and middle-income countries. In the nine-month-old target population, administration of S

Related Keywords

Kenya , United Kingdom , Switzerland , Limmatech Biologics , Alexander Siebert , Patricia Martin , Franz Werner Haas , Network Meeting , Trophic Communications , Wellcome , Chief Operating Officer , Annual Network Meeting , Wellcome Trust , Gram Negative Shigella , Tech Biologics , Werner Haas , Clinical Trial , Iologics , Accine Candidate , Diarrheal Disease , Immunogenicity , Tolerability Profile , Topline Results , Target Population , Shigellosis , Linical Development , Ioconjugate ,